FDA Misbranding Action Clarification Sought By WLF In Appeals Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA should not be allowed to pursue a misbranding action based solely on the dissemination of information that complies with the district court's injunction in Washington Legal Foundation v. Henney permitting manufacturer-sponsored dissemination of peer-reviewed journal articles and medical texts, WLF argues in its Nov. 8 appellate brief.
You may also be interested in...
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.